Intrapleural Corynebacterium parvum for malignant pleural effusions

Area of Science:

• Oncology
• Immunotherapy
• Pleural Diseases

Background:

• Malignant pleural effusions are a common complication of various cancers.
• Frequent thoracocentesis is often required for symptomatic relief, impacting patient quality of life.
• Novel treatment strategies are needed to manage malignant pleural effusions effectively.

Purpose of the Study:

• To evaluate the efficacy of intrapleural Corynebacterium parvum as a treatment for malignant pleural effusions.
• To assess the impact of this immunotherapy on fluid accumulation and cellular composition of pleural fluid.
• To identify patient subgroups that may benefit most from this therapeutic approach.

Main Methods:

• A pilot study involving 10 patients with malignant pleural effusions.
• Intrapleural administration of Corynebacterium parvum (7 mg in 20 ml saline) after fluid aspiration.
• Treatment repeated as needed based on clinical condition and fluid re-accumulation.

Main Results:

• Eight out of 10 patients experienced a reduced rate of pleural fluid accumulation.
• Significant changes in cell sediment composition were observed, including reduced or absent malignant cells.
• Increased lymphocyte and neutrophil polymorph counts in pleural fluid were noted.
• Primary pleural mesothelioma patients showed the best response.
• Clinical improvement was observed in all responding patients.

Conclusions:

• Intrapleural Corynebacterium parvum demonstrates potential as a treatment for malignant pleural effusions.
• The immunotherapy appears to modulate the local immune response within the pleural space.
• Further investigation is warranted, especially in patients with primary pleural mesothelioma.